CD274 and neoplasm: Recently, other biomarkers that aid prediction of response to immune checkpoint inhibitors such as tumor mutation burden (TMB) and microsatellite instability (MSI) have been emerging and PD-L1 expression alone is known to be an imperfect predictive biomarker.